Parkinson’s gene therapy AB-1005 trial moves forward in Europe
The first European patients in Askbio‘s Phase 2 clinical trial of AB-1005, an experimental gene therapy for Parkinson’s disease, have been randomly assigned to treatment groups. The study, REGENERATE-PD (NCT06285643), has begun randomizing participants at sites in Poland and the U.K. Trial sites in Germany are…